Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

NASDAQ PIRS opened at $13.60 on Wednesday. The firm has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. The firm has a 50 day simple moving average of $16.09 and a 200-day simple moving average of $14.71. Pieris Pharmaceuticals has a one year low of $6.20 and a one year high of $22.32.

Institutional Trading of Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals makes up 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. BML Capital Management LLC owned approximately 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.